Article Abstract:
Kodak acquired most of Imation's medical-imaging subsidiary for approximately $520 million, in an effort to strengthen its position atop the medical-imaging industry. Imation's DryView technology, which leads the dry laser-imaging systems market, can create instant films of images produced by magnetic-resonance imaging and CAT scans. Its use of digital technology bypasses lengthier and messier chemical processing for some applications. DryView's annual sales have exceeded 20% since its 1995 market introduction, and it presently represents around one-third of the company's annual revenue of $500 million, according to Imation. By comparison, the remainder of the medical-imaging industry is mature. Imation's estimates of an after-tax gain of between $75 million to $80 million on the deal pleased investors. Some analysts say Kodak may face regulatory hurdles, given its approximate 30% share of the international medical-imaging market.
User Contributions:
Comment about this article or add new information about this topic:
Article Abstract:
Eastman Kodak Co. agreed to buy most of Imation Corp.'s medical-imaging unit for about $520 million. The acquisition fills a major hole in Kodak's medical-products line. Imation is the leader in dry laser-imaging systems which are rapidly replacing traditional chemical-based films. Kodak ran into difficulties developing its own dry-laser technology. Imation said that the DryView line accounts for about one-third of its $500 million annual medical unit revenue, and sales of the line is growing by 20% annually.
User Contributions:
Comment about this article or add new information about this topic:
Article Abstract:
Bausch & Lomb Inc. has hired Warburg Dillon Reed LLC to help it review its options in regard to its sunglasses unit. Even though Ray-Ban and Revo brands have kept a 35% market share, the unit is under-performing compared with the firm's pharmaceutical and other segments. Possibilities include a spin-off, selling to a leveraged buy-out firm or a joint venture.
User Contributions:
Comment about this article or add new information about this topic: